We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

483 hedge funds and large institutions have $10.9B invested in Abiomed Inc in 2019 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 190 increasing their positions, 185 reducing their positions, and 111 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more repeat investments, than reductions

Existing positions increased: 190 | Existing positions reduced: 185

4% less capital invested

Capital invested by funds: $11.4B → $10.9B (-$468M)

14% less funds holding

Funds holding: 559483 (-76)

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

50% less call options, than puts

Call options by funds: $123M | Put options by funds: $247M

59% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 111

Holders
483
Holders Change
-76
Holders Change %
-13.6%
% of All Funds
10.49%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.09%
New
45
Increased
190
Reduced
185
Closed
111
Calls
$123M
Puts
$247M
Net Calls
-$124M
Net Calls Change
+$10.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.22B -$51.2M -192,869 -4%
BlackRock
2
BlackRock
New York
$883M +$77M +290,358 +9%
Primecap Management
3
Primecap Management
California
$816M -$4.78M -18,000 -0.6%
Renaissance Technologies
4
Renaissance Technologies
New York
$633M +$98.4M +370,800 +18%
Baillie Gifford & Co
5
Baillie Gifford & Co
United Kingdom
$578M +$302M +1,137,705 +105%
Sands Capital Management
6
Sands Capital Management
Virginia
$557M +$222M +835,078 +64%
State Street
7
State Street
Massachusetts
$492M +$6.87M +25,908 +1%
BCM
8
Brown Capital Management
Maryland
$354M +$33.4M +125,857 +10%
William Blair Investment Management
9
William Blair Investment Management
Illinois
$212M +$167M +629,455 +338%
AAMU
10
Amundi Asset Management US
Massachusetts
$197M +$28.7M +108,282 +17%
PAI
11
Palo Alto Investors
California
$184M +$2.04M +7,700 +1%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$174M +$31.8M +119,783 +22%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$171M +$7.54M +28,434 +5%
WRF
14
Waddell & Reed Financial
Kansas
$160M +$18.7M +70,605 +13%
Franklin Resources
15
Franklin Resources
California
$152M -$29M -109,444 -16%
FAM
16
Fred Alger Management
New York
$146M +$34.3M +129,359 +30%
Janus Henderson Group
17
Janus Henderson Group
United Kingdom
$145M -$25.4M -95,865 -15%
Norges Bank
18
Norges Bank
Norway
$134M +$6.59M +24,845 +5%
Artisan Partners
19
Artisan Partners
Wisconsin
$132M +$45.3M +170,652 +51%
American Century Companies
20
American Century Companies
Missouri
$127M +$13.4M +50,596 +12%
Northern Trust
21
Northern Trust
Illinois
$124M +$1.74M +6,554 +1%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$87.3M +$48.7M +183,400 +121%
CTA
23
Carillon Tower Advisers
Florida
$80.4M +$24.2M +91,218 +42%
Deutsche Bank
24
Deutsche Bank
Germany
$79.8M +$34.5M +130,194 +74%
Invesco
25
Invesco
Georgia
$79.1M +$17M +64,014 +27%

ABMD Hedge Fund Activity: Q2 2019 in Review

483 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q2 2019, worth a combined $10.9B — down 4.1% from $11.4B a quarter earlier.

Sellers outnumbered buyers: 111 funds closed out of ABMD and 45 opened new positions — a net loss of 66 holders — while 185 trimmed existing stakes and 190 added.

The largest buyer was Baillie Gifford & Co, adding an estimated $302M. The largest seller was AQR Capital Management, cutting an estimated $121M.

  • 483 institutional investors held Abiomed Inc (ABMD) as of Q2 2019, down from 559 in Q1 2019.
  • Funds reported $10.9B of Abiomed Inc stock for Q2 2019, down 4.1% quarter-over-quarter.
  • 45 funds opened new Abiomed Inc positions in Q2 2019 and 111 closed out, a net change of -66 holders.
  • The largest Abiomed Inc buyer in Q2 2019 was Baillie Gifford & Co, an estimated $302M added.
  • The largest Abiomed Inc seller in Q2 2019 was AQR Capital Management, an estimated $121M sold.

Based on aggregated 13F filings for Q2 2019.